ClinicalTrials.gov
public full text
Public Domain
Strategic Timing of Antiretroviral Treatment
Objectives: * To find out if the chance of developing a serious illness or of getting AIDS is less if patients start taking HIV medicines at a time when their cluster-of-differentiation-4 (CD4)+ cell count is still fairly high, instead of waiting until the CD4+ count is at the level where there is good evidence for starting medicines. * To learn more about how a strategy of starting HIV medicines early might affect other aspects of care, such as the chances of developing other illnesses or resistance to HIV medicines, the frequency of doctor visits, the cost of medical care, and general health and satisfaction.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Causes of hospitalization among people living with HIV in a tertiary-care hospital in Bogotá, Colombia, 2018-2024.#1159042
- The imperative for increased investment for an HIV cure#284307
- Acceptance of the Use of HIV Surveillance Data for Care Engagement#1250126
- Targeted Nurse-driven HIV Screening in Emergency Departments#1336916
- A Comparison of Two Ways to Manage Anti-HIV Treatment (The SMART Study)#1102524
Record · ID 1465942
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive